Biontech Se Sponsored Adr ((BNTX)), Biontech SE (($CC:BNTX.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioNTech SE, in collaboration with DualityBio Inc., is conducting a Phase III clinical study titled A Phase III, Randomized, Multi-site, Open-label Trial of BNT323/DB-1303 Versus Investigator’s Choice of Chemotherapy in Previously Treated Patients With HER2- Expressing Recurrent Endometrial Cancer. The study aims to evaluate the efficacy of BNT323/DB-1303 compared to standard chemotherapy in improving progression-free survival in patients with recurrent endometrial cancer who have previously undergone immune checkpoint inhibitor treatment.
The intervention being tested is BNT323/DB-1303, an investigational drug administered via intravenous infusion. It is compared against standard chemotherapy options, doxorubicin or paclitaxel, chosen by the investigator.
This open-label, randomized study employs a parallel intervention model with no masking. The primary purpose is treatment-focused, assessing the safety and efficacy of the new drug against existing chemotherapy options.
The study began on June 10, 2025, with primary completion expected in the coming months. The last update was submitted on August 19, 2025, indicating ongoing recruitment and data collection.
This study’s progress could significantly impact BioNTech’s stock performance, as positive results may enhance investor confidence and market position in the oncology sector. Competitors in the cancer treatment industry will closely monitor these developments.
The study is currently ongoing, with further details available on the ClinicalTrials portal.